Jun Zhu, MD
Peking University Cancer Hospital & Institute · Beijing Cancer Hospital, China · Peking University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jun Zhu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05716087 · A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD. · active not recruiting · Mantle Cell Lymphoma (MCL) · study chair
- Ph1/Ph2NCT04444141 · A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaAkeso · terminated · Peripheral T-cell Lymphoma · principal investigator
- Ph3NCT03670901 · A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)JHL Biotech, Inc. · terminated · Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT03655483 · Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaGuangzhou Gloria Biosciences Co., Ltd. · unknown · Classical Hodgkin's Lymphoma · principal investigator
- Ph1NCT03415399 · Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell LymphomaEureka Therapeutics Inc. · completed · Lymphoma, B-Cell · principal investigator
- Ph1NCT03208556 · Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell LymphomaPeking University · unknown · Relapsed or Refractory B-cell Lymphoma · principal investigator
- Ph2NCT03105596 · Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Peking University · unknown · B-cell Non-Hodgkin's Lymphoma · principal investigator
- Ph4NCT02905916 · The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After ChemotherapyPeking University · unknown · Mammary Cancer, Lymphoma, Bone Tumour · principal investigator
- Ph1NCT02842138 · Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell LymphomaPeking University · unknown · B-cell Lymphoma · principal investigator
- Ph4NCT02576327 · A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell TransplantationJun Zhu · unknown · Vomiting · principal investigator
- Ph4NCT02487316 · A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibJun Zhu · withdrawn · Systemic Anaplastic Large-Cell Lymphoma · study chair
- Ph2NCT02399189 · MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System LymphomaJun Zhu · unknown · Primary Central Nervous System Lymphoma · study chair
- Ph1/Ph2NCT02274584 · CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)Peking University · unknown · Lymphomas · principal investigator
- Ph1/Ph2NCT02247609 · Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell LymphomasPeking University · unknown · B-cell Lymphomas · principal investigator
- N/ANCT02108444 · Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma PatientsPeking University · completed · Hepatitis, Hepatitis B, Lymphoma · study chair
- Ph1NCT01919710 · Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat NeutropeniaTianjin SinoBiotech Ltd. · completed · Underdose (Unintentional), Cancer, Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.